Eczema
Also known as: Dermatitis, Allergy, Alrgy, Allergic, Allergies
Methodology & AI Transparency ⓘ
Eczema Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Eczema is a term for several different types of skin swelling.
- 2 Real-world patient consensus: Synonyms for Eczema (L20.9): Dermatitis, Allergy, Alrgy (Skin & Dermatology).
- 3 Typical cash cost range: Clinicians assessing Eczema focus on or pilosebaceous follicular in Eczema (L20.9: hyperkeratinization) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Eczema: maintaining Fasting Lipids & in Eczema (L20.9: ALT (if systemic) within Within baseline reference limits (L20.9).
Ask our AI Specialists anything about Eczema
What Is Eczema?
Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Eczema (L20.9) features or pilosebaceous follicular in Eczema (L20.9: hyperkeratinization). Cross-referenced with NIH MeSH (Eczema), therapeutic stabilization in skin & dermatology is verified against 25-Hydroxy Vitamin D in Eczema (L20.9: & hs-CRP).
Common Symptoms & Clinical Signs
- • Things that irritate your skin, such as certain soaps, fabrics, and lotions
- • Things you are allergic to, such as food, pollen, and animals
- • Presentation of Eczema (L20.9): persistent erythematous plaques, in Eczema (L20.9: scaly patches, pruritic)
- • Secondary Eczema clinical sign: compromised epidermal barrier in Eczema (L20.9: with dryness, fissuring,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Eczema Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L20.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Eczema (L20.9: ALT (if systemic) | Within baseline reference limits (L20.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Eczema (L20.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (L20.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Eczema (L20.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L20.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Eczema
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Roycederm Eczema Relief Cream (Colloidal Oatmeal 1%) Roycederm Eczema Relief Cream • RxCUI 240651-B85424010 | Non-Standardized Food Allergenic Extract | 92% | $0.9000 | $ 73.30 /mo |
| Triderma Eczema Fast Healing Face Body (E Relief) Triderma Eczema Fast Healing Face Body • RxCUI 1189915 | Non-Standardized Food Allergenic Extract | 83% | $2.7700 | $ 207.94 /mo |
| Colloidal Oatmeal Soothing Moisturizing, Eczema Itch Relief Wash and Shampo • RxCUI 2396990 | Non-Standardized Food Allergenic Extract | 81% | $3.3700 | $ 144.99 /mo |
| Serawise Eczema Relief (Oatmeal) Serawise Eczema Relief • RxCUI 240651-B85050012 | Non-Standardized Food Allergenic Extract | 93% | $3.3100 | $ 246.82 /mo |
| Eczema (Oatmeal) Eczema • RxCUI 1437616-B52915010 | Non-Standardized Food Allergenic Extract | 83% | $0.3200 | $ 31.54 /mo |
| Eczema Itch Relief Wash and Shampo (Colloidal Oatmeal) Eczema Itch Relief Wash and Shampo • RxCUI 2396990-B10738162 | Non-Standardized Food Allergenic Extract | 88% | $2.3500 | $ 177.70 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Eczema)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With: What a 639-Participant Study Found Delgocitinib cream resulted in clinically significant improvement in HRQoL compared with cream vehicle. Contact dermatitis • 2026-07-15 • Phase III Randomized Trial | N = 639 | 93/100 | PMID 41775339 ↗ |
| New Insights on Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients: What a 564-Participant Study Found LEB was associated with high rates of durable absolute EASI response, even in cases of high baseline severity or suboptimal week-16 outcomes. Acta dermato-venereologica • 2026-05-21 • Phase III Randomized Trial | N = 564 | 93/100 | PMID 42163822 ↗ |
| What the Latest Evidence Really Says About Factors associated with depression, anxiety and severe mental illness among Our review highlights limited existing research on factors associated with depression, anxiety and SMI in adults with AE or psoriasis. The British journal of dermatology • 2023-03-30 • Meta-Analysis | Multi-cohort | 92/100 | PMID 36745557 ↗ |
| Can This Approach Help? Inside the Latest Research on A multicenter, randomized, double-blinded, compared against a dummy pill Picankibart provided effective skin clearance in Chinese participants by week 16. Journal of the American Academy of Dermatology • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41937031 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of dupilumab in patients with severe chronic hand eczema with Dupilumab was efficacious and well tolerated. The British journal of dermatology • 2023-09-15 • Randomized Controlled Trial | N = 20 | 88/100 | PMID 37170922 ↗ |
Eczema Patient Community & “People Like Me” Threads
Filter Eczema community threads and patient logs by age, biological sex, dosage, and treatment duration.